<DOC>
	<DOCNO>NCT01704378</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate long-term safety biphasic insulin aspart 30 subject type 2 diabetes .</brief_summary>
	<brief_title>Efficacy Safety Biphasic Insulin Aspart 30 FlexPenâ„¢ Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Signed informed consent obtain trialrelated activity Completed trial BIAsp1236 Planned change use prescription medication may interfere glucose regulation Known suspect allergy trial product relate product Women intention become pregnant , judge use adequate contraceptive measure Any significant condition concomitant disease condition would interfere participation judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>